Yachiyo Kuwatsuka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yachiyo Kuwatsuka has a total of 360 co-authors. Here are the top co-authors by number of shared publications:
- Junya Kanda
Department of Hematology Graduate School of Medicine, Kyoto University Kyoto Japan
6 shared publications Takahiro Fukuda
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital
6 shared publications- Naoyuki Uchida
Department of Hematology Toranomon Hospital Tokyo Japan
5 shared publications Tetsuya Eto
Department of Hematology, Hamanomachi Hospital
5 shared publications- Yoshiko Atsuta
Japanese Data Center for Hematopoietic Cell Transplantation Nagakute Aichi Japan
5 shared publications - Hiroshi Arima
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine
4 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Elsevier in SSRN Electronic Journal
Tamibarotene, a Stromal-Targeting Retinoid, Plus Gemcitabine and Nab-Paclitaxel in Unresectable Pancreatic Cancer (MIKE-1): A Multicentre, Single-Arm, Open-Label, Phase 1/2 Trial
Background: In pancreatic ductal adenocarcinoma (PDAC), desmoplastic stroma limits drug delivery and contributes to therapeutic resistance. First-line gemcitabine plus nab-paclitaxel (GnP) has historically achieved an objective response rate (ORR) of about 23%, and no stromal-targeting approach has yet altered the first-line standard of care. Tamibarotene (AM80), a retinoid, induces tumour-restraining cancer-associated fibroblasts (rCAFs) in preclinical models, a reprogramming effect associated with improved intratumoural chemotherapy delivery. We evaluated tamibarotene plus GnP in patients with unresectable PDAC. Methods: MIKE-1 was an investigator-initiated, open-label, single-arm phase 1/2 trial in previously untreated unresectable PDAC. Phase 1, conducted at Nagoya University Hospital, used a 3+3 dose escalation design; phase 2 was undertaken at Nagoya University Hospital and University of Tokyo Hospital. Primary endpoints were determination of the recommended phase 2 dose in phase 1 and investigator-assessed confirmed ORR per RECIST version 1·1 in phase 2. Findings: Between March 2022 and April 2025, 60 patients were enrolled and 59 started treatment. At data cutoff (2 October 2025; median follow-up 12·7 months), the confirmed ORR in phase 2 (n=42; tamibarotene 8 mg/day on days 1–14 plus GnP) was 50·0% (21/42; 90% CI 36·5–63·5; p<0·001 vs the prespecified historical 23% threshold), and the disease control rate was 85·7% (36/42). Median progression-free survival was 11·3 months, median overall survival was not reached, and 12-month overall survival was 86·9% (95% CI 71·0–94·4). Interstitial lung disease (ILD) occurred in seven (16·7%) of 42 patients; all improved or resolved, and no grade 5 treatment-related adverse events occurred. In 12 phase 1/2 paired-biopsy patients, Xenium spatial transcriptomics showed an on-treatment shift away from myofibroblastic CAFs (myCAFs) towards rCAFs. Interpretation: Tamibarotene plus GnP exceeded the prespecified ORR threshold, with paired-biopsy increases in stromal Meflin and a myCAF-to-rCAF shift consistent with stromal reprogramming. A randomised trial versus GnP alone, with prospective ILD monitoring, is warranted.
- 4 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTamibarotene, a Stromal-Targeting Retinoid, Plus Gemcitabine and Nab-Paclitaxel in Unresectable Pancreatic Cancer (MIKE-1): A Multicentre, Single-Arm, Open-Label, Phase 1/2 Trial
Background: In pancreatic ductal adenocarcinoma (PDAC), desmoplastic stroma limits drug delivery and contributes to therapeutic resistance. First-line gemcitabine plus nab-paclitaxel (GnP) has historically achieved an objective response rate (ORR) of about 23%, and no stromal-targeting approach has yet altered the first-line standard of care. Tamibarotene (AM80), a retinoid, induces tumour-restraining cancer-associated fibroblasts (rCAFs) in preclinical models, a reprogramming effect associated with improved intratumoural chemotherapy delivery. We evaluated tamibarotene plus GnP in patients with unresectable PDAC. Methods: MIKE-1 was an investigator-initiated, open-label, single-arm phase 1/2 trial in previously untreated unresectable PDAC. Phase 1, conducted at Nagoya University Hospital, used a 3+3 dose escalation design; phase 2 was undertaken at Nagoya University Hospital and University of Tokyo Hospital. Primary endpoints were determination of the recommended phase 2 dose in phase 1 and investigator-assessed confirmed ORR per RECIST version 1·1 in phase 2. Findings: Between March 2022 and April 2025, 60 patients were enrolled and 59 started treatment. At data cutoff (2 October 2025; median follow-up 12·7 months), the confirmed ORR in phase 2 (n=42; tamibarotene 8 mg/day on days 1–14 plus GnP) was 50·0% (21/42; 90% CI 36·5–63·5; p<0·001 vs the prespecified historical 23% threshold), and the disease control rate was 85·7% (36/42). Median progression-free survival was 11·3 months, median overall survival was not reached, and 12-month overall survival was 86·9% (95% CI 71·0–94·4). Interstitial lung disease (ILD) occurred in seven (16·7%) of 42 patients; all improved or resolved, and no grade 5 treatment-related adverse events occurred. In 12 phase 1/2 paired-biopsy patients, Xenium spatial transcriptomics showed an on-treatment shift away from myofibroblastic CAFs (myCAFs) towards rCAFs. Interpretation: Tamibarotene plus GnP exceeded the prespecified ORR threshold, with paired-biopsy increases in stromal Meflin and a myCAF-to-rCAF shift consistent with stromal reprogramming. A randomised trial versus GnP alone, with prospective ILD monitoring, is warranted.
- 5 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1293.e1-1293.e12
Adjusting Disease Risk Index for Regional Variations and Donor Selection
- 5 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1293.e1-1293.e12
Adjusting Disease Risk Index for Regional Variations and Donor Selection
- Open Access
- 1 June 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (2) , e70139
A Preliminary Open‐Label Pilot Study of a Pillow‐Based ELF ‐ ELME (Extremely Low‐Frequency, Extremely Low Magnetic Environment) Intervention for Major Depressive Disorder
Background: Mitochondrial dysfunction has been implicated in the pathogenesis of depression. Major depressive disorder (MDD) is a prevalent condition with substantial individual and societal burden. A novel approach—exposure to an extremely low‐frequency, extremely low magnetic environment (ELF‐ELME)—has shown promise. This preliminary study builds on a previous trial using a head‐mounted ELF‐ELME device and explores the potential efficacy and safety of a pillow‐based ELF‐ELME device in patients with MDD. Methods: In this preliminary open‐label pilot study, four patients with MDD were treated using a pillow‐based ELF‐ELME device (10 μTesla, 4 ms, 1–8 Hz/8 s) for 2 h daily over 8 weeks. The primary outcome was change in Montgomery–Åsberg Depression Rating Scale (MADRS) scores from baseline to Week 8. Artificial Intelligence‐based MADRS (AI‐MADRS) scores were also assessed. Results: Total MADRS scores showed a unidirectional decrease from baseline (33.8 ± 7.3) to Week 8 (21.5 ± 8.7; p = 0.050, FDR = 0.067), and no time point reached statistical significance after FDR correction. In contrast, AI‐MADRS scores significantly decreased from baseline (34.0 ± 8.3) to Week 8 (19.8 ± 6.8; p = 0.040). No serious adverse events were reported. Conclusion: These preliminary findings suggest that an 8‐week course of pillow‐based ELF‐ELME intervention may have potential to alleviate depressive symptoms in patients with MDD. However, given the small sample size and open‐label design, the results should be interpreted with caution. Larger controlled studies are warranted to confirm these findings. Trial Registration: jRCT number: jRCTs042240061; https://jrct.mhlw.go.jp/en‐latest‐detail/jRCTs042240061
- 1 June 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (2) , e70139
Open AccessA Preliminary Open‐Label Pilot Study of a Pillow‐Based ELF ‐ ELME (Extremely Low‐Frequency, Extremely Low Magnetic Environment) Intervention for Major Depressive Disorder
Background: Mitochondrial dysfunction has been implicated in the pathogenesis of depression. Major depressive disorder (MDD) is a prevalent condition with substantial individual and societal burden. A novel approach—exposure to an extremely low‐frequency, extremely low magnetic environment (ELF‐ELME)—has shown promise. This preliminary study builds on a previous trial using a head‐mounted ELF‐ELME device and explores the potential efficacy and safety of a pillow‐based ELF‐ELME device in patients with MDD. Methods: In this preliminary open‐label pilot study, four patients with MDD were treated using a pillow‐based ELF‐ELME device (10 μTesla, 4 ms, 1–8 Hz/8 s) for 2 h daily over 8 weeks. The primary outcome was change in Montgomery–Åsberg Depression Rating Scale (MADRS) scores from baseline to Week 8. Artificial Intelligence‐based MADRS (AI‐MADRS) scores were also assessed. Results: Total MADRS scores showed a unidirectional decrease from baseline (33.8 ± 7.3) to Week 8 (21.5 ± 8.7; p = 0.050, FDR = 0.067), and no time point reached statistical significance after FDR correction. In contrast, AI‐MADRS scores significantly decreased from baseline (34.0 ± 8.3) to Week 8 (19.8 ± 6.8; p = 0.040). No serious adverse events were reported. Conclusion: These preliminary findings suggest that an 8‐week course of pillow‐based ELF‐ELME intervention may have potential to alleviate depressive symptoms in patients with MDD. However, given the small sample size and open‐label design, the results should be interpreted with caution. Larger controlled studies are warranted to confirm these findings. Trial Registration: jRCT number: jRCTs042240061; https://jrct.mhlw.go.jp/en‐latest‐detail/jRCTs042240061
- 17 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 994.e1-994.e11
Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial
- 17 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 994.e1-994.e11
Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
Efficacy and Safety of Trifluridine/Tipiracil Plus Ramucirumab in Later-Line Treatment of Advanced Gastric Cancer: A Multicenter, Prospective Phase II Trial
PURPOSE: Trifluridine/tipiracil (FTD/TPI) plus ramucirumab may improve survival as a later-line therapy for advanced gastric cancer (GC); however, prospective evidence is limited. PATIENTS AND METHODS: We conducted a multicenter, prospective phase II trial of FTD/TPI plus ramucirumab in patients with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma who had received at least two previous systemic regimens for advanced disease, including a ramucirumab-containing regimen. Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received oral FTD/TPI (35 mg/m 2 , days 1-5 and 8-12) and ramucirumab (8 mg/kg, days 1 and 15) every 28 days. The primary end point was time to treatment failure (TTF), and the secondary end points were progression-free survival (PFS), overall survival (OS), response, disease control rate (DCR), relative dose intensity (RDI), and safety. RESULTS: Between February 2022 and March 2024, 32 patients were enrolled (median age, 72.5 years; 53.1% male). The median TTF was 4.0 months (95% CI, 2.8 to 5.0), meeting the primary end point. Median PFS and OS were 4.8 (95% CI, 2.8 to 8.3) and 12.2 months (95% CI, 7.8 to 17.2), respectively. Among 26 patients with measurable disease, objective response rate was 11.5%, and DCR was 76.9%. Mean RDI was 78.6% for FTD/TPI and 93.1% for ramucirumab, supporting feasibility in this cohort. Grade ≥3 neutropenia occurred in 53.1% and febrile neutropenia in 9.4%. Frequent nonhematologic events were anorexia (68.8%) and fatigue (59.4%), mostly grade 1 to 2. A modified FTD/TPI schedule was introduced in 15 patients and maintained dose delivery while reducing neutropenia, with no febrile events. CONCLUSION: FTD/TPI plus ramucirumab met its primary end point and was feasible with manageable safety in heavily pretreated advanced GC. Given the single-arm design, the efficacy findings are hypothesis-generating and warrant confirmation in larger randomized trials.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
Efficacy and Safety of Trifluridine/Tipiracil Plus Ramucirumab in Later-Line Treatment of Advanced Gastric Cancer: A Multicenter, Prospective Phase II Trial
PURPOSE: Trifluridine/tipiracil (FTD/TPI) plus ramucirumab may improve survival as a later-line therapy for advanced gastric cancer (GC); however, prospective evidence is limited. PATIENTS AND METHODS: We conducted a multicenter, prospective phase II trial of FTD/TPI plus ramucirumab in patients with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma who had received at least two previous systemic regimens for advanced disease, including a ramucirumab-containing regimen. Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received oral FTD/TPI (35 mg/m 2 , days 1-5 and 8-12) and ramucirumab (8 mg/kg, days 1 and 15) every 28 days. The primary end point was time to treatment failure (TTF), and the secondary end points were progression-free survival (PFS), overall survival (OS), response, disease control rate (DCR), relative dose intensity (RDI), and safety. RESULTS: Between February 2022 and March 2024, 32 patients were enrolled (median age, 72.5 years; 53.1% male). The median TTF was 4.0 months (95% CI, 2.8 to 5.0), meeting the primary end point. Median PFS and OS were 4.8 (95% CI, 2.8 to 8.3) and 12.2 months (95% CI, 7.8 to 17.2), respectively. Among 26 patients with measurable disease, objective response rate was 11.5%, and DCR was 76.9%. Mean RDI was 78.6% for FTD/TPI and 93.1% for ramucirumab, supporting feasibility in this cohort. Grade ≥3 neutropenia occurred in 53.1% and febrile neutropenia in 9.4%. Frequent nonhematologic events were anorexia (68.8%) and fatigue (59.4%), mostly grade 1 to 2. A modified FTD/TPI schedule was introduced in 15 patients and maintained dose delivery while reducing neutropenia, with no febrile events. CONCLUSION: FTD/TPI plus ramucirumab met its primary end point and was feasible with manageable safety in heavily pretreated advanced GC. Given the single-arm design, the efficacy findings are hypothesis-generating and warrant confirmation in larger randomized trials.
- Open Access
- 3 September 2025
- Published by Springer Nature in Research Square
Adjusting Disease Risk Index for Regional Variations and Donor Selection: TRUMP cohort study
The Disease Risk Index (DRI) is a widely used prognostic tool following hematopoietic stem cell transplantation (HSCT), based on disease classification and status. However, the refined DRI (rDRI) does not fully account for regional variations in disease distribution and treatment practices. We analyzed 7,720 patients with hematologic malignancies who underwent their first allogeneic HSCT between 2014 and 2016 and developed a region-adjusted DRI (raDRI) using the Japanese registry database. We then validated predictive performance in 5,108 patients transplanted between 2017 and 2018. The raDRI demonstrated superior accuracy compared with the rDRI (time-dependent AUC: 0.705 vs. 0.670; integrated calibration index: 0.016 vs. 0.017). In patients with low to intermediate raDRI, matched related donors were associated with improved overall survival compared with matched unrelated bone marrow donors (bone marrow: hazard ratio (HR) 0.50, 95% CI 0.26 - 0.96; peripheral blood HR 0.54, 95% CI 0.36-0.83), whereas no differences were seen in patients with high to very high raDRI. Our findings suggest that disease risk should be carefully interpreted considering disease distribution and donor source.
- 3 September 2025
- Published by Springer Nature in Research Square
Open AccessAdjusting Disease Risk Index for Regional Variations and Donor Selection: TRUMP cohort study
The Disease Risk Index (DRI) is a widely used prognostic tool following hematopoietic stem cell transplantation (HSCT), based on disease classification and status. However, the refined DRI (rDRI) does not fully account for regional variations in disease distribution and treatment practices. We analyzed 7,720 patients with hematologic malignancies who underwent their first allogeneic HSCT between 2014 and 2016 and developed a region-adjusted DRI (raDRI) using the Japanese registry database. We then validated predictive performance in 5,108 patients transplanted between 2017 and 2018. The raDRI demonstrated superior accuracy compared with the rDRI (time-dependent AUC: 0.705 vs. 0.670; integrated calibration index: 0.016 vs. 0.017). In patients with low to intermediate raDRI, matched related donors were associated with improved overall survival compared with matched unrelated bone marrow donors (bone marrow: hazard ratio (HR) 0.50, 95% CI 0.26 - 0.96; peripheral blood HR 0.54, 95% CI 0.36-0.83), whereas no differences were seen in patients with high to very high raDRI. Our findings suggest that disease risk should be carefully interpreted considering disease distribution and donor source.
- Open Access
- 30 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , e382-e389
The Time of the Hypertonic Saline Infusion Test for the Diagnosis of AVP Deficiency Can Be Shortened With LC-MS/MS
Context: In clinical practice, plasma arginine vasopressin (AVP) concentrations have been measured with a radioimmunoassay (RIA). However, RIAs have limitations, such as long turnaround time, use of radioisotopes, and restricted antibody availability. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers a promising alternative, eliminating the need for radioisotopes and antibodies while providing faster results. Objective: This study aimed to assess the usefulness of LC-MS/MS for measuring plasma AVP concentrations in diagnosing AVP deficiency (AVP-D). Methods: We included 16 patients with AVP-D and 28 controls. All participants underwent a hypertonic saline infusion test (HST), during which plasma AVP concentrations were measured using RIA and LC-MS/MS. Regression coefficients (gradients) for serum sodium vs plasma AVP concentrations were evaluated at 90 and 120 minutes, and receiver-operating characteristic analyses were performed based on these regression coefficients. Results: The area under the receiver-operating characteristic curve at 90 minutes was 0.97 (95% CI, 0.83-1.00) and 0.93 (95% CI, 0.80-0.98) for LC-MS/MS and RIA, respectively. A regression gradient cutoff with optimal values distinguished AVP-D from controls with a sensitivity of 100% in LC-MS/MS and RIA, whereas the specificity was 96% and 81% with LC-MS/MS and RIA, respectively. Sensitivity or specificity did not differ in 120 minutes between the 2 methods. Conclusion: LC-MS/MS demonstrated superior diagnostic accuracy for AVP-D at 90 minutes of HST, indicating that the HST time can be shortened from 120 to 90 minutes by measuring AVP with LC-MS/MS. Clinical trial registration: The study was registered with the University Hospital Medical Information Network (UMIN) registry (UMIN000043023).
- 30 July 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , e382-e389
Open AccessThe Time of the Hypertonic Saline Infusion Test for the Diagnosis of AVP Deficiency Can Be Shortened With LC-MS/MS
Context: In clinical practice, plasma arginine vasopressin (AVP) concentrations have been measured with a radioimmunoassay (RIA). However, RIAs have limitations, such as long turnaround time, use of radioisotopes, and restricted antibody availability. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers a promising alternative, eliminating the need for radioisotopes and antibodies while providing faster results. Objective: This study aimed to assess the usefulness of LC-MS/MS for measuring plasma AVP concentrations in diagnosing AVP deficiency (AVP-D). Methods: We included 16 patients with AVP-D and 28 controls. All participants underwent a hypertonic saline infusion test (HST), during which plasma AVP concentrations were measured using RIA and LC-MS/MS. Regression coefficients (gradients) for serum sodium vs plasma AVP concentrations were evaluated at 90 and 120 minutes, and receiver-operating characteristic analyses were performed based on these regression coefficients. Results: The area under the receiver-operating characteristic curve at 90 minutes was 0.97 (95% CI, 0.83-1.00) and 0.93 (95% CI, 0.80-0.98) for LC-MS/MS and RIA, respectively. A regression gradient cutoff with optimal values distinguished AVP-D from controls with a sensitivity of 100% in LC-MS/MS and RIA, whereas the specificity was 96% and 81% with LC-MS/MS and RIA, respectively. Sensitivity or specificity did not differ in 120 minutes between the 2 methods. Conclusion: LC-MS/MS demonstrated superior diagnostic accuracy for AVP-D at 90 minutes of HST, indicating that the HST time can be shortened from 120 to 90 minutes by measuring AVP with LC-MS/MS. Clinical trial registration: The study was registered with the University Hospital Medical Information Network (UMIN) registry (UMIN000043023).
- 16 July 2025
- Published by Wiley in British Journal of Haematology
A win ratio approach for comparing graft‐versus‐host disease‐free, relapse‐free survival among alternative donors
Summary: The optimal alternative donor type for patients lacking human leucocyte antigen (HLA)‐matched related or unrelated donors remains unclear. In comparative studies evaluating donor types, graft‐versus‐host disease (GVHD)‐free, relapse‐free survival (GRFS) represents a well‐established end‐point but has limitations. The win ratio approach addresses these limitations by analysing multiple end‐points with varying severities to account for the relative component priorities. We compared HLA‐mismatched unrelated donors, haploidentical donors and cord blood using both the hazard ratio (HR) of GRFS and the win ratio related to GRFS. The haploidentical donor group had a similar HR of GRFS (HR: 1.01, 95% confidence interval [CI]: 0.85–1.19, p = 0.916) and win ratio (win ratio: 0.86, 95% CI: 0.72–1.02, p = 0.081) to HLA‐mismatched unrelated donors. Cord blood transplantation showed similar GRFS compared to HLA‐mismatched unrelated donors in the Cox proportional model (HR: 1.14, 95% CI: 0.98–1.32, p = 0.085), significantly lower win ratio (win ratio: 0.80, 95% CI: 0.68–0.93, p = 0.004) and similar outcomes to haploidentical donors. HLA‐mismatched unrelated donor transplantation showed comparable to superior outcomes among alternative donor types. Our results indicate the need to present the win ratio alongside conventional methods to assess the end‐point robustly.
- 16 July 2025
- Published by Wiley in British Journal of Haematology
A win ratio approach for comparing graft‐versus‐host disease‐free, relapse‐free survival among alternative donors
Summary: The optimal alternative donor type for patients lacking human leucocyte antigen (HLA)‐matched related or unrelated donors remains unclear. In comparative studies evaluating donor types, graft‐versus‐host disease (GVHD)‐free, relapse‐free survival (GRFS) represents a well‐established end‐point but has limitations. The win ratio approach addresses these limitations by analysing multiple end‐points with varying severities to account for the relative component priorities. We compared HLA‐mismatched unrelated donors, haploidentical donors and cord blood using both the hazard ratio (HR) of GRFS and the win ratio related to GRFS. The haploidentical donor group had a similar HR of GRFS (HR: 1.01, 95% confidence interval [CI]: 0.85–1.19, p = 0.916) and win ratio (win ratio: 0.86, 95% CI: 0.72–1.02, p = 0.081) to HLA‐mismatched unrelated donors. Cord blood transplantation showed similar GRFS compared to HLA‐mismatched unrelated donors in the Cox proportional model (HR: 1.14, 95% CI: 0.98–1.32, p = 0.085), significantly lower win ratio (win ratio: 0.80, 95% CI: 0.68–0.93, p = 0.004) and similar outcomes to haploidentical donors. HLA‐mismatched unrelated donor transplantation showed comparable to superior outcomes among alternative donor types. Our results indicate the need to present the win ratio alongside conventional methods to assess the end‐point robustly.
- Open Access
- 26 August 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (11) , 1692-1705
Safety and Tolerability of Adipose-Derived Mesenchymal Stem Cell (ADR-001) Therapy for IgA Nephropathy
Key Points: IgA nephropathy often requires KRT. Mesenchymal stem cells offer clinical benefits. Adipose-derived mesenchymal stem cells are safe and tolerable. Background: IgA nephropathy (IgAN) often requires KRT because of its refractoriness and because corticosteroids pose infection risks. However, mesenchymal stem cells offer clinical benefits because of their regenerative and immunomodulatory properties. This prospective clinical trial assessed the safety and tolerability of adipose-derived mesenchymal stem cell (ASC) therapy and evaluated its therapeutic efficacy. Methods: This phase 1 study included adult patients with refractory IgAN that was difficult to treat with traditional therapies. ASC therapy comprising one intravenous dose of 1×108 cells was administered to three to six patients in Cohort 1. The same intravenous dose was administered twice with a 2-week interval to six patients in Cohort 2. Heparin was administered simultaneously. This study continued for 52 weeks, and the primary end points were safety and tolerability during the 6-week period after treatment administration. Secondary end points included adverse events and efficacy measures such as clinical remission, partial remission, urine protein remission, hematuria remission, time to remission, changes in the urine protein and hematuria levels, and changes in the eGFR. Results: The three patients in Cohort 1 and six patients in Cohort 2 who received ASC therapy achieved the primary end points. No severe adverse clinical events were observed. Therefore, the safety and tolerability of ASCs were confirmed. Improvements, such as significantly decreased kidney damage markers and urinary protein levels, were observed immediately after ASC administration. Conclusions: The safety and tolerability of ASCs are acceptable for patients with IgAN. Clinical Trial registry name and registration number: This trial was registered with the Japan Registry of Clinical Trials (jRCT2043200002; registration date: April 14, 2020) and ClinicalTrials.gov (NCT04342325; registration date: April 13, 2020).
- 26 August 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (11) , 1692-1705
Open AccessSafety and Tolerability of Adipose-Derived Mesenchymal Stem Cell (ADR-001) Therapy for IgA Nephropathy
Key Points: IgA nephropathy often requires KRT. Mesenchymal stem cells offer clinical benefits. Adipose-derived mesenchymal stem cells are safe and tolerable. Background: IgA nephropathy (IgAN) often requires KRT because of its refractoriness and because corticosteroids pose infection risks. However, mesenchymal stem cells offer clinical benefits because of their regenerative and immunomodulatory properties. This prospective clinical trial assessed the safety and tolerability of adipose-derived mesenchymal stem cell (ASC) therapy and evaluated its therapeutic efficacy. Methods: This phase 1 study included adult patients with refractory IgAN that was difficult to treat with traditional therapies. ASC therapy comprising one intravenous dose of 1×108 cells was administered to three to six patients in Cohort 1. The same intravenous dose was administered twice with a 2-week interval to six patients in Cohort 2. Heparin was administered simultaneously. This study continued for 52 weeks, and the primary end points were safety and tolerability during the 6-week period after treatment administration. Secondary end points included adverse events and efficacy measures such as clinical remission, partial remission, urine protein remission, hematuria remission, time to remission, changes in the urine protein and hematuria levels, and changes in the eGFR. Results: The three patients in Cohort 1 and six patients in Cohort 2 who received ASC therapy achieved the primary end points. No severe adverse clinical events were observed. Therefore, the safety and tolerability of ASCs were confirmed. Improvements, such as significantly decreased kidney damage markers and urinary protein levels, were observed immediately after ASC administration. Conclusions: The safety and tolerability of ASCs are acceptable for patients with IgAN. Clinical Trial registry name and registration number: This trial was registered with the Japan Registry of Clinical Trials (jRCT2043200002; registration date: April 14, 2020) and ClinicalTrials.gov (NCT04342325; registration date: April 13, 2020).
- Open Access
- 20 July 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (10) , 1027.e1-1027.e14
Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation
- 20 July 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (10) , 1027.e1-1027.e14
Open AccessImpact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation